BRPI0606326A2 - n-aminometileno sulfonamidas substituìdas, produção e uso das mesmas como medicamentos - Google Patents

n-aminometileno sulfonamidas substituìdas, produção e uso das mesmas como medicamentos

Info

Publication number
BRPI0606326A2
BRPI0606326A2 BRPI0606326-8A BRPI0606326A BRPI0606326A2 BR PI0606326 A2 BRPI0606326 A2 BR PI0606326A2 BR PI0606326 A BRPI0606326 A BR PI0606326A BR PI0606326 A2 BRPI0606326 A2 BR PI0606326A2
Authority
BR
Brazil
Prior art keywords
aminomethylene
sulfonamides
production
substituted
medicinal products
Prior art date
Application number
BRPI0606326-8A
Other languages
English (en)
Inventor
Guenter Mueller
Karl-Heinz Baringhaus
Karl Schoenafinger
Stefan Petry
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0606326A2 publication Critical patent/BRPI0606326A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

N-AMINOMETILENO SULFONAMIDAS SUBSTITUìDAS, PRODUçãO E USO DAS MESMAS COMO MEDICAMENTOS. A presente invenção refere-se a compostos de fórmula geral (I), em que a definição dos substituintes R^ 1^ - R^ 5^, A e X estão dadas no relatório descritivo, e aos sais fisiologicamente compatíveis dos mesmos. A invenção também refere-se a um método para produzir os referidos compostos e ao uso dos mesmos como medicamentos. Os referidos compostos inventivos são inibidores da lipase sensível a hormónio (HSL).
BRPI0606326-8A 2005-01-17 2006-01-16 n-aminometileno sulfonamidas substituìdas, produção e uso das mesmas como medicamentos BRPI0606326A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005002130A DE102005002130A1 (de) 2005-01-17 2005-01-17 Substituierte N-Aminomethylensulfonamide, ihre Herstellung und Verwendung als Arzneimittel
PCT/EP2006/000313 WO2006074957A1 (de) 2005-01-17 2006-01-16 Substituierte n-aminomethylensulfonamide, ihre herstellung und verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
BRPI0606326A2 true BRPI0606326A2 (pt) 2009-06-16

Family

ID=36650366

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606326-8A BRPI0606326A2 (pt) 2005-01-17 2006-01-16 n-aminometileno sulfonamidas substituìdas, produção e uso das mesmas como medicamentos

Country Status (15)

Country Link
US (1) US7781613B2 (pt)
EP (1) EP1841731B1 (pt)
JP (1) JP2008526914A (pt)
KR (1) KR20070094789A (pt)
CN (1) CN101107222A (pt)
AR (1) AR056265A1 (pt)
AU (1) AU2006205823A1 (pt)
BR (1) BRPI0606326A2 (pt)
CA (1) CA2601343A1 (pt)
DE (1) DE102005002130A1 (pt)
IL (1) IL184526A0 (pt)
MX (1) MX2007008611A (pt)
TW (1) TW200637810A (pt)
UY (1) UY29337A1 (pt)
WO (1) WO2006074957A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
CN104502513B (zh) * 2015-01-14 2016-04-06 中国矿业大学连云港徐圩新区高新技术研究院 一种对羧基苯磺酰胺的高效液相色谱测定方法
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
WO2020033919A1 (en) 2018-08-10 2020-02-13 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009910A (en) * 1960-01-04 1961-11-21 Merck & Co Inc 2, 4-disulfamyl-aniline derivatives
DE2419970C3 (de) * 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2518999A1 (de) * 1975-04-29 1976-11-18 Hoechst Ag Verfahren zur herstellung von sulfamylbenzoesaeuren
DE2836085A1 (de) 1978-08-17 1980-03-06 Hoechst Ag Sulfamoylbenzolderivate und verfahren zu ihrer herstellung
HU207051B (en) * 1987-12-30 1993-03-01 Chinoin Gyogyszer Es Vegyeszet Process for producing 4-chloro-3-sulfamoylbenzoic acid hydrazides and pharmaceutical compositions comprising such compounds
HU198458B (en) * 1987-12-30 1989-10-30 Chinoin Gyogyszer Es Vegyeszet Process for producing 2-aminoisoquinoline derivatives and pharmaceutical compositions comprising these compounds
KR20040068240A (ko) 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
WO2003105860A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase

Also Published As

Publication number Publication date
US20080069851A1 (en) 2008-03-20
EP1841731A1 (de) 2007-10-10
MX2007008611A (es) 2008-01-14
UY29337A1 (es) 2006-08-31
AU2006205823A1 (en) 2006-07-20
US7781613B2 (en) 2010-08-24
AR056265A1 (es) 2007-10-03
TW200637810A (en) 2006-11-01
WO2006074957A9 (de) 2007-07-12
DE102005002130A1 (de) 2006-07-27
IL184526A0 (en) 2007-10-31
JP2008526914A (ja) 2008-07-24
KR20070094789A (ko) 2007-09-21
CN101107222A (zh) 2008-01-16
CA2601343A1 (en) 2006-07-20
EP1841731B1 (de) 2012-08-22
WO2006074957A1 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
BRPI0606326A2 (pt) n-aminometileno sulfonamidas substituìdas, produção e uso das mesmas como medicamentos
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0318811B8 (pt) derivados de ciclohexanol espirocíclicos
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0513901A (pt) derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
BRPI0413490A (pt) novos compostos
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
BRPI0507198A (pt) derivados de bisariluréia
BR112013020996A8 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BRPI0510847A (pt) compostos inibidores de dpp-iv, sais farmaceuticamente aceitáveis e pró-fármacos dos mesmos, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
BRPI0607583A2 (pt) derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BR112013000189A2 (pt) compostos de piridina anelados
BRPI0514310A (pt) 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos
BRPI0507830A (pt) derivados azabicìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
BRPI0510849A (pt) compostos inibidores de dpp-iv, sais farmaceuticamente aceitáveis e pró-fármacos dos mesmos, composição farmacêutica compreendendo os mesmo e uso dos referidos compostos na fabricação de medicamento
AR058348A1 (es) Derivados de 1-aza-biciclo-nonano y composiciones farmaceuticas que los comprenden

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]